Results 61 to 70 of about 2,285,787 (260)

Efficacy of anti-CD147 chimeric antigen receptors targeting hepatocellular carcinoma

open access: yesNature Communications, 2020
Chimeric antigen receptor (CAR)-based therapy for the treatment of liver cancer represents a promising therapeutic strategy. Here the authors show that CD147-targeting CAR-NK or CAR-T can induce anti-tumor activity against hepatocellular carcinoma in ...
Hsiang-chi Tseng   +14 more
doaj   +1 more source

Adoptive Cellular Therapy in Acute Myeloid Leukemia: Current Scope and Challenges

open access: yesHematology/Oncology and Stem Cell Therapy, 2022
Adoptive cellular therapies have revolutionized the management of hematologic malignancies, particularly lymphoma and multiple myeloma. These therapies targeting disease-specific antigens, such as CD19 in lymphoma and B cell maturation antigen in ...
Sankalp Arora   +4 more
doaj   +1 more source

SOX5 Orchestrates Malignant Evolution via Promoter‐Centric Chromatin Remodeling in MYC‐Driven B‐Cell Lymphoma

open access: yesAdvanced Science, EarlyView.
In MYC‐enforced B‐cell lymphoma, SOX5 occupies promoter‐proximal regulatory regions and is associated with reduced chromatin accessibility at the PCNP locus. PCNP repression promotes proliferative remodeling by limiting apoptosis and cell‐cycle restraint.
Yiyou Mao   +6 more
wiley   +1 more source

Efficacy and safety of Chimeric Antigen Receptor T-Cell (CAR-T) therapy in hematologic malignancies: A living systematic review

open access: yes, 2023
This living systematic review aims to provide a timely, rigorous and continuously updated summary of the evidence available on the role of Chimeric Antigen Receptor T-Cell (CAR-T) therapy for the treatment of patients with hematologic ...
Juan Erviti   +10 more
core   +1 more source

Redirecting Monocyte Differentiation With Engineered Extracellular Vesicles for Glioma Immunotherapy

open access: yesAdvanced Science, EarlyView.
A dual‐targeting engineered extracellular vesicles (M1‐CS‐EVs) platform is developed to redirect monocytes differentiation into anti‐tumor macrophages for glioma immunotherapy. This nanoplatform combines CAR‐mediated tumor recognition with localized CD47 blockade, leading to synergistic immune activation and potent suppression of tumor progression in ...
Yuanwei Pan   +9 more
wiley   +1 more source

Immunotherapy Deriving from CAR-T Cell Treatment in Autoimmune Diseases

open access: yesJournal of Immunology Research, 2019
Chimeric antigen receptor T (CAR-T) cells are T cells engineered to express specific synthetic antigen receptors that can recognize antigens expressed by tumor cells, which after the binding of these antigens to the receptors are eliminated, and have ...
Yuehong Chen   +4 more
doaj   +1 more source

Chimeric IL‐6/4R‐LL37 Engineered Macrophages Achieve Synchronized Inflammation Control and Antimicrobial Defence in Sepsis

open access: yesAdvanced Science, EarlyView.
Engineered macrophages programmed in situ by LNP‐delivered IL‐6/4 fusion and LL37 mRNAs simultaneously dampen cytokine storm, promote M2‐like repair, and enhance direct bacterial killing in sepsis. This combinatorial strategy restores T cell and macrophage function, lowers organ bacterial burden, and improves survival, highlighting a precision, host ...
Tianyang Jie   +10 more
wiley   +1 more source

Repurposing a Small Molecule Plant Hormone as a Tunable ON‐Switch for CAR‐T Cell Immunotherapy

open access: yesAdvanced Science, EarlyView.
By engineering a receptor system integrating the plant auxin receptor AFB1 with its co‐receptor IAA7, we enable ligand‐dependent interactions triggered by the plant hormone auxins. This design allows rapid, reversible, and dose‐dependent T cell activation, resulting in potent cytotoxicity against B‐cell lymphoma in vitro and in vivo.
Hongxiang Zeng   +16 more
wiley   +1 more source

IFI27 and BAX are Essential for GSDME‐Mediated Myeloma Cell Pyroptosis

open access: yesAdvanced Science, EarlyView.
The proposed model of GSDME‐mediated MM cell pyroptosis modulated by IFI27 and BAX. IFI27 is downregulated in MM cells. Upon pyroptotic stimulation, such as DOX or ETO treatment, IFI27 is induced, therefore liberating BAX from BCL‐2 ❶. BAX is then recruited to mitochondria and forms homo‐oligomeric channels in OMM, therefore leading to cytochrome C ...
Yaoli Cui   +12 more
wiley   +1 more source

Utility and Drawbacks of Chimeric Antigen Receptor T Cell (CAR-T) Therapy in Lung Cancer

open access: yes, 2022
The present treatments for lung cancer include surgical resection, radiation, chemotherapy, targeted therapy, and immunotherapy. Despite advances in therapies, the prognosis of lung cancer has not been substantially improved in recent years.
Kobold, S.   +15 more
core   +1 more source

Home - About - Disclaimer - Privacy